US biotech firm Moderna has said in a press release on Monday that its mRNA-based candidate anti-Covid19 vaccine has proven to be 94.5 percent effective in phase three clinical trials.
“This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%,” Moderna added.
The biotech company said that the vaccine was “generally well tolerated,” although side effects such as fatigue, myalgia, and headaches were reported in a minority of participants.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” Stephane Bancel, Moderna’s chief executive officer, said in the press release.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.